Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 24 Non-Muscle Invasive Bladder Neoplasms 5 Hematuria 4 Pain 2 Carcinoma, Transitional Cell 2 Carcinoma in Situ 2 Urinary Bladder Neck Obstruction 1 Urinary Bladder Diseases 1 Urinary Bladder Calculi 1 Ureteral Neoplasms 1 Prostatic Neoplasms 1 Prostatic Hyperplasia 1 Pain, Postoperative 1 Nephrolithiasis 1 Neoplasms 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Lower Urinary Tract Symptoms 1 Kidney Neoplasms 1 Kidney Diseases 1 Disease 1 Anxiety Disorders 1

Interventions

Gemcitabine 13 pembrolizumab 9 Specimen Handling 9 enfortumab vedotin 8 Cisplatin 8 Magnetic Resonance Spectroscopy 7 avelumab 5 Carboplatin 5 vinflunine 4 Nivolumab 4 atezolizumab 3 Immunoglobulin G 3 Disulfides 3 Biopsy 3 eribulin 2 cabozantinib 2 Standard of Care 2 Ramucirumab 2 Radiotherapy 2 Platinum 2 Nephroureterectomy 2 Ipilimumab 2 Doxorubicin 2 Docetaxel 2 CTLA-4 Antigen 2 Bortezomib 2 1,2-diaminocyclohexaneplatinum II citrate 2 vandetanib 1 tremelimumab 1 tocilizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Cystoscopy × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡